{
    "Disease activity (follow up: 4 months; assessed with: ACR 20)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": [
            "serious",
            "a"
        ],
        "Imprecision": [
            "very serious",
            "b"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "MTX monotherapy": "88/180 (48.9%)",
            "LEF": "95/182 (52.2%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.94 (0.76 to 1.15)",
            "Absolute (95% CI)": "31 fewer per 1,000 (from 125 fewer to 78 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 4 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)": {
        "No of studies": "2",
        "Study design": "randomised trials",
        "Risk of bias": [
            "serious",
            "c"
        ],
        "Inconsistency": "not serious",
        "Indirectness": [
            "serious",
            "a"
        ],
        "Imprecision": [
            "very serious",
            "d"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "MTX monotherapy": "21",
            "LEF": "19"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.67 lower (1.5 lower to 0.16 higher)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    }
}